Research map: GLP ‐1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real‐World Study of Lifestyle Pre‐Treatment, Time‐Limited Treatment Cap, and Post‐Cessation Regain

Back to the article

Papers in this map

  1. Once-Weekly Semaglutide in Adults with Overweight or Obesity · John P.H. Wilding · 2021 · 5054 citations · Cited by this paper
  2. Economic Impact of Multidisciplinary Pre‐operative Diabetes Care Versus Usual Care in Adults Undergoing Elective Non‐cardiac Surgery in Australia: A Trial‐Based Analysis · 2026 · Related
  3. Tirzepatide Once Weekly for the Treatment of Obesity · Ania M. Jastreboff · 2022 · 3661 citations · Cited by this paper
  4. Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease · 2026 · Related
  5. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · A. Michael Lincoff · 2023 · 3058 citations · Cited by this paper
  6. Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy · 2026 · Related
  7. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines For Medical Care of Patients with Obesity · William Timothy Garvey · 2016 · 1903 citations · Cited by this paper
  8. Trends and Prevalence of Undiagnosed Dysglycemia Among Reproductive‐Age Women in the United States · 2026 · Related
  9. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation · George A. Bray · 2017 · 1610 citations · Cited by this paper
  10. Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study · 2026 · Related
  11. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity · Domenica Rubino · 2021 · 1405 citations · Cited by this paper
  12. Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment‐Resistant Non‐Diabetic Obesity: A Retrospective Pilot Study · 2026 · Related
  13. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline · Caroline M. Apovian · 2015 · 1348 citations · Cited by this paper
  14. Exercise Snacks Are Feasible to Perform in the Real World and Improve Physical Capacity for Adults Living With Non‐Insulin Treated Type 2 Diabetes: A Randomised Trial · 2026 · Related
  15. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension · John P.H. Wilding · 2022 · 1076 citations · Cited by this paper
  16. Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD ) · 2026 · Related
  17. Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis · Rohit Seth Loomba · 2024 · 942 citations · Cited by this paper
  18. Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease · 2026 · Related
  19. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial · William Timothy Garvey · 2022 · 862 citations · Cited by this paper
  20. Methodological and Conceptual Concerns Regarding the 24‐h Glycaemia/C‐Peptide Ratio as a Novel Insulin Sensitivity Index · 2026 · Related
  21. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity · Louis J. Aronne · 2023 · 825 citations · Cited by this paper
  22. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity · Atul Malhotra · 2024 · 816 citations · Cited by this paper
  23. Tirzepatide for Obesity Treatment and Diabetes Prevention · Ania M. Jastreboff · 2024 · 441 citations · Cited by this paper
  24. Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan · Wataru Ogawa · 2023 · 200 citations · Cited by this paper
  25. Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery · Jessica Mok · 2023 · 178 citations · Cited by this paper
  26. Disparities in Access and Quality of Obesity Care · Tiffani Bell Washington · 2023 · 137 citations · Cited by this paper
  27. Race, Ethnicity, Sex, and Obesity: Is It Time to Personalize the Scale? · Fatima Cody Stanford · 2019 · 61 citations · Cited by this paper
  28. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity · Deborah Bade Horn · 2025 · 41 citations · Cited by this paper
  29. Obesity management: at the forefront against disease stigma and therapeutic inertia · Luca Busetto · 2021 · 38 citations · Cited by this paper
  30. International lack of equity in modern obesity therapy: the critical need for change in health policy · Pia Roser · 2022 · 35 citations · Cited by this paper
  31. The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference · Susan L. Furth · 2025 · 28 citations · Cited by this paper
  32. Japan initiates market authorization of weight‐loss drug semaglutide under universal health coverage, but with stringent prescription restrictions · Hayase Hakariya · 2024 · 12 citations · Cited by this paper
  33. The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: a systematic review and meta-analysis · Asma Mousavi · 2025 · 12 citations · Cited by this paper
  34. Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery · Hussein Abdallah · 2025 · 11 citations · Cited by this paper
  35. Modeling potential cost‐effectiveness of tirzepatide versus lifestyle modification for patients with overweight and obesity · Meredith M. Hoog · 2025 · 7 citations · Cited by this paper

Source: OpenAlex (CC0)